|
Getting your Trinity Audio player ready...
|
By Omboki Monayo
Nairobi, Kenya: The global fight against heart disease achieved a significant milestone this week with the publication of a landmark study in The Lancet. The review, titled “New drug therapies for hypertension,” reveals a pivotal shift from daily pill regimens to long-acting “biologic” treatments, a transition that could fundamentally reshape the management of high blood pressure worldwide.
Led by a team of researchers including Prof. Michel Azizi and Prof. Katherine Tuttle, the study highlights a new era of molecular-level control. At the heart of this shift is a novel class of RNA-interference (RNAi) therapies. These treatments function more like a vaccine than traditional medicine, offering sustained blood pressure control for months at a time.
The Breakthrough: From Daily Pills to Twice-a-Year Injections
For decades, hypertension patients have adhered to a “pill-a-day” routine. However, the study identifies Zilebesiran, an investigational injectable therapy, as a potential game-changer. Unlike standard beta-blockers or ACE inhibitors that must be taken every 24 hours, Zilebesiran works by “silencing” the genetic instructions in the liver responsible for producing angiotensinogen, the protein that narrows blood vessels.
Clinical data from the KARDIA trials, cited in the report, show that a single subcutaneous injection can maintain stable, lowered blood pressure for up to six months. The review also highlights next-generation Aldosterone Synthase Inhibitors (ASIs), such as Lorundrostat. These offer high precision in blocking hormones that cause salt retention, providing a new lifeline for patients whose condition was previously considered “untreatable.”
The Kenyan Context: A Silent Emergency
For Kenya, the arrival of these therapies could not be more timely, addressing a growing public health crisis. While infectious diseases often dominate headlines, hypertension has established itself as a “silent killer” across the country. Data from the Ministry of Health indicates that between 24% and 28% of Kenyan adults are living with high blood pressure.
The statistics are sobering: cardiovascular diseases now account for approximately 13% of all deaths in Kenya, with high blood pressure being the leading driver. It is responsible for thousands of cases of premature stroke, heart failure, and kidney disease every year. Perhaps most alarming is the “Rule of Halves” currently observed within the local health system: only half of those with the condition are ever diagnosed, and of those, less than 7% manage to keep their blood pressure under control.
Why This Matters for Africa
Health experts assert that the true value of these long-acting injections for Africa lies in their potential to solve the chronic problem of “patient non-adherence.” In many parts of Kenya, the daily ritual of taking medication is often disrupted by the high cost of monthly refills, long distances to pharmacies, or the fact that patients frequently stop taking drugs because they do not “feel” sick.
By shifting to a twice-a-year injection model, these logistical burdens are largely removed. A patient in a rural area would only need to visit a clinic twice a year to ensure continuous 24-hour protection, effectively eliminating the risks of forgetting a dose or running out of supplies.
The Expected Impact and the Road Ahead
The potential impact on Kenya’s healthcare economy is significant. By preventing catastrophic events like strokes and kidney failure, the country could save millions in emergency care and lost productivity. However, the path from the laboratory to the local clinic remains a matter of policy.
For these “vaccine-like” treatments to be effective on a large scale, they must be integrated into Kenya’s Universal Health Coverage (UHC) framework and included in the Social Health Authority (SHA) benefits package and the National Essential Medicines List. As the study concludes, while the science has arrived, the next critical challenge will be regional price negotiation to ensure equitable access.
